Anika Therapeutics Reports Officer and Director Changes

Ticker: ANIK · Form: 8-K · Filed: Apr 10, 2025 · CIK: 898437

Anika Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAnika Therapeutics, Inc. (ANIK)
Form Type8-K
Filed DateApr 10, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: leadership-change, officer-appointment, director-election, compensation

TL;DR

Anika Therapeutics filed an 8-K for officer/director changes and compensation arrangements as of April 4, 2025.

AI Summary

Anika Therapeutics, Inc. filed an 8-K on April 10, 2025, reporting events as of April 4, 2025. The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. Specific details regarding the individuals involved and the nature of these changes were not provided in the excerpt.

Why It Matters

Changes in a company's board of directors or executive officers can signal shifts in strategy, governance, or operational focus.

Risk Assessment

Risk Level: medium — Changes in key leadership and compensation can impact company direction and investor confidence.

Key Players & Entities

  • Anika Therapeutics, Inc. (company) — Registrant
  • Delaware (jurisdiction) — State of Incorporation
  • 32 Wiggins Avenue, Bedford, MA 01730 (address) — Principal Executive Offices

FAQ

What specific events are being reported in this 8-K filing?

The 8-K filing reports on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers.

What is the exact date of the earliest event reported?

The date of the earliest event reported is April 4, 2025.

When was this Form 8-K filed with the SEC?

This Form 8-K was filed as of April 10, 2025.

What is Anika Therapeutics, Inc.'s state of incorporation?

Anika Therapeutics, Inc. is incorporated in Delaware.

What is the address of Anika Therapeutics, Inc.'s principal executive offices?

The address of Anika Therapeutics, Inc.'s principal executive offices is 32 Wiggins Avenue, Bedford, MA 01730.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 10, 2025 regarding Anika Therapeutics, Inc. (ANIK).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.